Experts raise concerns about an AI tool that predicts brain tumor growth
Original title: Biological domain shift and statistical nesting concerns in generative AI-based spatial tumor growth prediction for pediatric diffuse midline glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a comment on other research, not a new result.
The short version
This is a comment on an AI study, not a new treatment.
What was studied. Another team built an AI tool to predict tumor growth on MRI scans. It was made for children with a brain tumor called diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. These experts looked at how that study was done. The outside test group had only 13 patients.
What they found. The AI was good at outlining the whole tumor. It did much worse at predicting where the tumor would grow. The experts say the tool learned from both adult and child tumors, which are not the same. They also say many scan slices came from a few patients, so the results may look stronger than they are.
What this means, and what it doesn't
What it could mean: Nothing about your care changes today. This is scientists talking about how such AI tools should be tested before doctors use them.
What it doesn't mean: This is not a treatment, and it is not a cure. No drug or therapy was tested here. The AI tool is still early research. It is not used to plan care for patients now. It would need much more testing in more children first.
Source: PubMed, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.